97 related articles for article (PubMed ID: 10554804)
1. Long-term survival in multiple myeloma: a Finnish Leukaemia Group study.
Br J Haematol; 1999 Jun; 105(4):942-7. PubMed ID: 10554804
[TBL] [Abstract][Full Text] [Related]
2. Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. Finnish Leukaemia Group.
Oivanen TM
Br J Haematol; 1996 Mar; 92(4):834-9. PubMed ID: 8616075
[TBL] [Abstract][Full Text] [Related]
3. Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study.
Oivanen TM; Kellokumpu-Lehtinen P; Koivisto AM; Koivunen E; Palva I
Eur J Haematol; 1999 Feb; 62(2):109-16. PubMed ID: 10052714
[TBL] [Abstract][Full Text] [Related]
4. Response rate and survival after conventional chemotherapy for multiple myeloma by hospitals with different inclusion rates of patients to the trials. A Finnish Leukemia Group study.
Oivanen T; Kellokumpu-Lehtinen P; Koivisto AM; Koivunen E
Eur J Haematol; 1999 Oct; 63(4):225-30. PubMed ID: 10530410
[TBL] [Abstract][Full Text] [Related]
5. Improved long-term survival in multiple myeloma. Finnish Leukaemia Group.
Eur J Haematol; 1989 Nov; 43(5):385-8. PubMed ID: 2612611
[TBL] [Abstract][Full Text] [Related]
6. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].
Pertuiset E; Chevret S; Lioté F; Delauche MC; Bardin T; Dryll A; Kuntz D
Ann Med Interne (Paris); 1992; 143(8):519-24. PubMed ID: 1303595
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of serum M-protein doubling time at escape from plateau of multiple myeloma. The Finnish Leukaemia Group.
Oivanen TM
Eur J Haematol; 1996 Sep; 57(3):247-53. PubMed ID: 8898930
[TBL] [Abstract][Full Text] [Related]
8. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
9. [Long-term survival and prognostic factors in multiple myeloma treated with conventional chemotherapy. Report of 109 cases].
Ben Abid H; Meddeb B; Ben Abdallah M; Bel Hadj Ali Z; Hafsia R; Ben Lakhal R; Gouider E; Aissaoui L; Landoulsi I; ben Abdeladhim A; Hafsia A
Tunis Med; 2000 Dec; 78(12):705-12. PubMed ID: 11155374
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
Yakoub-Agha I; Attal M; Dumontet C; Delannoy V; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux V; Bay JO; Monconduit M; Harousseau JL; Duguet C; Duhamel A; Facon T
Hematol J; 2002; 3(4):185-92. PubMed ID: 12189564
[TBL] [Abstract][Full Text] [Related]
11. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland.
Karjalainen S; Palva I
BMJ; 1989 Oct; 299(6707):1069-72. PubMed ID: 2511967
[TBL] [Abstract][Full Text] [Related]
12. Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.
Riccardi A; Ucci G; Luoni R; Brugnatelli S; Mora O; Spanedda R; De Paoli A; Barbarano L; Di Stasi M; Alberio F
Br J Cancer; 1994 Dec; 70(6):1203-10. PubMed ID: 7981078
[TBL] [Abstract][Full Text] [Related]
13. VAD-PECC regimen in the treatment of advanced-stage multiple myeloma.
Delain M; Linassier C; Petitdidier C; Goupille P; Luthier F; Combe M; Reisenleiter M; Benboubker L; Lamagnère JP; Colombat P
J Clin Oncol; 1994 Dec; 12(12):2706-13. PubMed ID: 7989948
[TBL] [Abstract][Full Text] [Related]
14. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
15. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
Harousseau JL; Attal M; Divine M; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M; Abgrall JF
Stem Cells; 1995 Aug; 13 Suppl 2():132-9. PubMed ID: 8520502
[TBL] [Abstract][Full Text] [Related]
17. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
[TBL] [Abstract][Full Text] [Related]
18. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
19. A prognostic index for multiple myeloma.
Grignani G; Gobbi PG; Formisano R; Pieresca C; Ucci G; Brugnatelli S; Riccardi A; Ascari E
Br J Cancer; 1996 May; 73(9):1101-7. PubMed ID: 8624271
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
Minarik J; Scudla V; Ordeltova M; Bacovsky J; Pika T; Langova K
Eur J Haematol; 2009 Dec; 83(6):528-34. PubMed ID: 19624720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
